1 / 15

“Fighting Cancer: It’s All We Do.” ™

“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects. Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate Professor Of Medicine Detroit Medical Center Wayne State University/ Karmanos Cancer Institute, Detroit MI. Metastatic Prostate Cancer.

evette
Télécharger la présentation

“Fighting Cancer: It’s All We Do.” ™

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Fighting Cancer: It’s All We Do.”™

  2. Restoring Quality of LifeAndManaging Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate Professor Of Medicine Detroit Medical Center Wayne State University/ Karmanos Cancer Institute, Detroit MI.

  3. Metastatic Prostate Cancer • Common site of spread- bones • Incurable, likely terminal condition • Morbidity significant as it can lead to bone pain,cord compression, fractures, urinary obstruction etc. • Initial therapy with hormones which is effective, but temporary

  4. Metastatic disease: hormone therapy • Hormone therapy questions: • When to start? • Continuous vs intermittent • Which kind: Lupron/Zoladex with casodex or casodex alone (50 mg daily) or high dose casodex 150 mg daily • Should we stop treatment when it stops working? • What are the risks?

  5. Common Complications of Hormone Therapy • Fatigue • Metabolic syndrome- high blood sugar, high cholesterol • Increased risk of heart problems in people who have heart disease • Hot flashes • Impotence • Osteoporosis • Gynecomastia and breast tenderness • Mood swings • Liver toxicity • Diarrhea, nausea

  6. Strategies to address side effects of hormone therapy • Hormone therapy works by suppressing the male hormone/testosterone levels. • Fighting the side effects: -Increased Awareness -Stay active - Healthy diet • Ask for medication therapy for hot flashes if bothersome. • Consider intermittent hormone therapy if feasible • Monitor cholesterol, blood sugars periodically.

  7. Supportive Care in Advanced Prostate Cancer • Bone strengthening therapy • Radiation • Pain control therapies • Chemotherapy/novel agents

  8. Zometa vs. Placebo in Hormone Refractory Metastatic Prostate Cancer Berruti et al, JNCI 2003

  9. Frequency of skeletal complications due to bone metastasis Median time to first skeletal-related event compared with placebo 50 44% 100 40 33% 80 Not reached 30 60 Patients Without Event (%) P=0.011 321 days 20 40 20 10 0 0 0 50 100 150 200 250 300 350 400 450 Placebo Zoledronic acid Days After Start of Therapy Bisphosphonates for Treatmentof Bone Metastasis

  10. Dietary factors • Lycopene: A minimum of 2 servings (1 cup) per week of tomato sauce can reduce the risk of development and progression of prostate cancer. • Cruciferous vegetables: at least five servings per week can decrease the risk of developing prostate cancer by 20%. • Green Tea may have possible protective effects • A large study showed that too much calcium (over 2000mg daily) can increase metastatic prostate cancer risk fivefold compared with those consuming <500 mg daily- Health Professionals Follow Up study

  11. Dietary factors • Vitamins within the recommended daily intake are recommended • Overdosage of vitamins maybe potentially harmful • Male smokers study in Finland showed that Vitamin E supplementation decreased the incidence of prostate cancer by 32% and the mortality related to prostate cancer by 41%. Beta carotene (Vit A) increased risk of lung cancer • Finasteride/Proscar prevented prostate cancer and reduced the risk by 25% • Selenium and Vit E trial completed and no benefit noted.

  12. Systemic Therapy in Treatment of Prostate Cancer • Discuss use of systemic therapy in metastatic prostate cancer to a} Prolong life b}Palliation or symptom control • In locally advanced prostate cancer, the goal is to improve cure rate and keep long term toxicity to a minimum

  13. Development of Hormonal Escape Androgen-independentcells take over Depriveandrogen Responsive Cell numbers Dependent Independent Time Prostate Cancer. London, England: Times Mirror International Publishers Ltd;1996:143.

  14. Metastatic Disease • Therapy in hormone refractory disease • Supportive care and palliation options: Currently approved • Chemotherapy • Bisphosphonate therapy • Radioisotope therapy

  15. “Fighting Cancer: It’s All We Do.”™

More Related